Downregulation of Protein tyrosine kinase 6 (PTK6), a non-receptor tyrosine kinase highly expressed in HER2+ breast cancer, led to p38 activation, Bim induction and apoptosis of Lapatinib-resistant HER2+ breast cancer cells [500]. Here, ERBB2 is linked to breast cancer.